Dogwood Therapeutics Inc. (DWTX)
5.64
-0.23 (-3.92%)
At close: Apr 24, 2025, 3:59 PM
5.70
1.05%
After-hours: Apr 24, 2025, 07:58 PM EDT
Company Description
Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response.
The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia.
It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID.
The company was formerly known as Virios Therapeutics, Inc. and changed its name to Dogwood Therapeutics, Inc. in October 2024.
The company was founded in 2012 and is headquartered in Alpharetta, Georgia.
Dogwood Therapeutics Inc.
| Country | United States |
| IPO Date | n/a |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 12 |
| CEO | Gregory Duncan |
Contact Details
Address: 44 Milton Avenue Alpharetta, Georgia United States | |
| Website | https://www.dwtx.com |
Stock Details
| Ticker Symbol | DWTX |
| Exchange | NASDAQ |
| Fiscal Year | n/a |
| Reporting Currency | USD |
| CIK Code | n/a |
| CUSIP Number | n/a |
| ISIN Number | US92829J2033 |
| Employer ID | - |
| SIC Code | n/a |
Key Executives
| Name | Position |
|---|---|
| Gregory Duncan | Chairman & Chief Executive Officer |
| Angela Walsh | Chief Financial Officer, Secretary & Treasurer |
| Carol Duffy Ph.D. | Chief Scientific Advisor |
| Dr. R. Michael Gendreau M.D., Ph.D. | Chief Medical Officer |
| Dr. William L. Pridgen M.D. | Founder & Member of Scientific Advisory Board |
| Ralph D. Grosswald M.P.H. | Senior Vice President of Operations |